Teva: A Complete Overview
Summary
An overview of Teva's business model and growth prospects.
Focusing on the company's solid sales growth and its drive to blockbuster earnings growth.
Reviewing its explosive product pipeline and acquisition growth and targets.
Examining potential price gains and reviewing risks the company faces
Beyond its existing product pipeline, the company has over 330 products awaiting approval in its developed markets and over 600 products awaiting approval in its growth markets not yet fully penetrated, expecting over 1,500 new products to be launched globally in 2017.
The company expects to lay off roughly 7,000 employees by year end alongside closing 15 plants around the globe whilst existing markets in over 45 countries.
These efforts and more are set to save Teva almost $1.5B annually.
Source: Seeking Alpha
https://seekingalpha.com/article/410303 ... ngcom_feed